An interventional study of Basic MTM and Enhanced MTM in HIV Infections, sponsored by Universiti Sains Malaysia. Completed at 1 site in Sudan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Universiti Sains Malaysia · Not applicable, Interventional, and Health services research
This clinical trial aims to evaluate the effectiveness and cost-effectiveness of two levels of a pharmacist-led Medication Therapy Management (MTM) program, Basic MTM and Enhanced MTM, compared with usual care for HIV patients at high risk of adverse drug events in Khartoum, Sudan.
The primary objective is to determine whether Basic MTM or Enhanced MTM improves medication adherence, measured by the Proportion of Days Covered (PDC ≥95%) at the primary 6-month assessment, with follow-up continuing for 24 months. Secondary objectives include evaluating the effects of the interventions on viral load suppression, CD4+ cell count, adverse drug events, drug-related problems, health-related quality of life, patient satisfaction, treatment self-efficacy, and cost-effectiveness.
Participants will be randomly assigned in a 1:1:1 ratio to one of three study groups:
Arm 1: Usual Care Arm 2: Basic Medication Therapy Management (Basic MTM) Arm 3: Enhanced Medication Therapy Management (Enhanced MTM)
All participants will attend study visits at baseline and at 6, 12, 18, and 24 months to complete study questionnaires and undergo routine clinical assessments, including viral load and CD4+ measurements.
Participants assigned to the Basic MTM group will receive usual care plus structured pharmacist-led Medication Therapy Management, including comprehensive medication reviews, a personal medication record, a medication action plan, five face-to-face MTM visits (baseline and every six months thereafter), and four scheduled telephone follow-up calls over the 24-month study period.
Participants assigned to the Enhanced MTM group will receive all components of Basic MTM together with more frequent face-to-face visits, monthly during the first three months and every three months thereafter, additional telephone support for high-risk participants, adherence support tools (such as pill organizers and medication reminder tools), enhanced communication with prescribers, and home visits when appropriate.
Do these MTM interventions improve clinical outcomes, such as viral load suppression and CD4+ cell count, compared to usual care?
Researchers will compare three groups (Arm 1: Usual Care; Arm 2: Basic MTM; Arm 3: Enhanced MTM) to determine whether the MTM interventions lead to better medication adherence, fewer adverse drug events, improved quality of life, and greater cost-effectiveness.
Participants will:
Be randomly assigned to one of three groups: Usual Care, Basic MTM, or Enhanced MTM.
Attend scheduled research assessment visits at baseline, 6, 12, 18, and 24 months to complete questionnaires (on adherence, quality of life, etc.) and provide blood samples for routine lab tests (viral load, CD4 count).
If assigned to Basic MTM: Participate in 4 face-to-face sessions and 4 telephone follow-ups with a trained pharmacist over 24 months for medication reviews, education, and adherence support.
If assigned to Enhanced MTM: Participate in 8 face-to-face sessions and 8 telephone follow-ups with a trained pharmacist over 24 months, and receive enhanced support tools (e.g., pillboxes, alarm devices) and potentially home visits.
This three-arm, parallel-group, open-label randomized controlled trial evaluates the effectiveness and cost-effectiveness of two levels of pharmacist-led Medication Therapy Management (MTM), Basic MTM and Enhanced MTM, compared with usual care among HIV patients at high risk of adverse drug events in Khartoum, Sudan. The study also includes an implementation evaluation guided by the Consolidated Framework for Implementation Research (CFIR).
Participants are randomly assigned in a 1:1:1 ratio to one of three study arms using a computer-generated random sequence prepared by an independent statistician. Randomization is performed using variable block sizes and is stratified by study site and baseline viral suppression status. Allocation concealment is maintained using sequentially numbered, sealed, opaque envelopes opened only after completion of baseline assessments.
Because of the nature of the MTM intervention, participants and pharmacist investigators are not blinded to treatment allocation. Laboratory personnel responsible for viral load and CD4 measurements and the independent statistician performing the primary analyses remain blinded to treatment allocation.
The primary analysis follows the intention-to-treat principle and includes all randomized participants. Missing outcome data are handled using multiple imputation by chained equations (MICE). A prespecified per-protocol sensitivity analysis includes participants who complete at least 80% of scheduled MTM visits and have complete outcome data. Primary and secondary outcomes are assessed over a 24-month follow-up period using appropriate statistical methods specified in the study protocol.
The study includes clinical, patient-reported, economic, and implementation outcomes, including medication adherence, viral load suppression, CD4+ cell count, adverse drug events, drug-related problems, health-related quality of life, treatment self-efficacy, patient satisfaction, and cost-effectiveness.
Study oversight is provided by the Trial Steering Committee, which reviews study progress and data annually. No formal interim analyses or stopping rules are planned because the study evaluates a low-risk pharmacist-led behavioral intervention. Any protocol deviations are documented and managed according to the study protocol.
4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.
This study's enrollment of 1,149 is above the median of 80 across 3,489 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →Universiti Sains Malaysia is the lead sponsor of 177 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ART Duration: Receiving antiretroviral therapy (ART) for at least 3 months prior to enrollment.
--Language and Consent: Able to communicate in Arabic or English and willing and able to provide written .
Viral load >200 copies/mL during the previous 6 months.
--Self-reported medication adherence \<95% or repeated missed clinic appointments.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the Usual Care arm received the standard HIV care routinely provided at the participating study sites in Sudan. Standard care included scheduled physician follow-up visits, routine clinical and laboratory monitoring (including viral load and CD4+ cell count assessments), monthly antiretroviral medication refills with routine dispensing counseling, and management according to national HIV treatment guidelines. No structured Medication Therapy Management (MTM) services or dedicated pharmacist-led follow-up beyond usual care were provided.
Participants in Arm 2 received usual care plus a structured pharmacist-led Basic Medication Therapy Management (MTM) program over 24 months. The intervention included comprehensive medication reviews (CMRs) at enrollment and every 6 months, a Personal Medication Record (PMR), a Medication Action Plan (MAP), five face-to-face MTM visits at months 0, 6, 12, 18, and 24 (45 to 60 minutes each), and four scheduled telephone follow-up calls at months 3, 9, 15, and 21 (15 to 20 minutes each). Drug-related problems were identified and addressed during each CMR, with pharmacist-to-prescriber communication provided when appropriate. Participants did not receive the enhanced MTM components, such as structured peer support sessions, adherence aids, or home visits.
Behavioral: Basic MTM
Participants in Arm 3 received usual care plus an enhanced pharmacist-led Medication Therapy Management (MTM) program over 24 months. The intervention included all components of Basic MTM, together with more frequent face-to-face visits (monthly during the first 3 months and every 3 months thereafter), home visits or additional telephone follow-up for high-risk participants, structured peer support group sessions, adherence support tools (including pill organizers and medication reminder tools), enhanced pharmacist-to-prescriber communication with participation in multidisciplinary team meetings, and additional pharmacist training in motivational interviewing and CFIR-informed implementation strategies.
Behavioral: Enhanced MTM
A structured pharmacist-led Medication Therapy Management (MTM) program delivered over 24 months in addition to usual care. The intervention includes comprehensive medication reviews (CMRs), development of a Personal Medication Record (PMR) and a Medication Action Plan (MAP), patient education, medication adherence assessment and support, identification and resolution of drug-related problems, and pharmacist communication with prescribers when appropriate. Participants receive five face-to-face MTM visits at baseline and every 6 months thereafter (months 0, 6, 12, 18, and 24), together with four scheduled telephone follow-up calls at months 3, 9, 15, and 21. Participants in this group do not receive the additional support components provided in the Enhanced MTM intervention.
An enhanced pharmacist-led Medication Therapy Management (MTM) program delivered over 24 months in addition to usual care. The intervention includes all components of the Basic MTM program, including comprehensive medication reviews (CMRs), a Personal Medication Record (PMR), a Medication Action Plan (MAP), patient education, medication adherence assessment and support, identification and resolution of drug-related problems, and pharmacist communication with prescribers when appropriate. Participants receive more frequent face-to-face MTM visits, monthly during the first 3 months and every 3 months thereafter, together with additional telephone follow-up for high-risk participants. Enhanced MTM also includes structured peer support group sessions, adherence support tools (including pill organizers and medication reminder tools), enhanced collaboration with prescribers through multidisciplinary team particip
Medication Adherence - Proportion of Days Covered (PDC)
Medication adherence will be assessed using the Proportion of Days Covered (PDC) calculated from pharmacy refill records as: (days covered by dispensed medication ÷ days in the observation period) × 100. Optimal adherence is defined as PDC ≥95%.
Time frame: Baseline, 6 months (primary endpoint), 12 months, 18 months, and 24 months
Viral Load Suppression
Proportion of participants achieving plasma HIV RNA \<200 copies/mL at each assessment time point
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
CD4+ Cell Count
Absolute CD4+ T-lymphocyte count measured by flow cytometry. Analyses include the change in CD4+ cell count from baseline and the proportion of participants achieving CD4+ cell counts \>500 cells/µL.
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Adverse Drug Events (ADEs) - Incidence
Number and severity of adverse drug events (ADEs) occurring during the study period. ADEs are defined as any untoward medical occurrence associated with medication use and are classified according to standardized severity criteria.
Time frame: From enrollment through 24 months
Adverse Drug Events (ADEs) - Severity Distribution
Distribution of adverse drug events (ADEs) according to severity (mild, moderate, severe, and life-threatening) using standardized severity classification criteria. Results will be reported as the proportion of ADEs within each severity category.
Time frame: From enrollment through 24 months
Drug-Related Problems (DRPs)
Number and types of drug-related problems (DRPs) identified using the modified Pharmaceutical Care Network Europe (PCNE) Classification Version 9.1. DRPs will be classified according to PCNE categories and reported as the number of DRPs identified per participant.
Time frame: Baseline, 6 months, 12 months, 18 months, and 24 months (MTM arms only)
Medication Self-Efficacy Score
Medication self-efficacy assessed using the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES), a 12-item instrument in which each item is rated on a scale from 0 (cannot do at all) to 10 (certain can do). Total scores range from 0 to 120, with higher scores indicating greater self-efficacy and confidence in taking medications as prescribed."
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Number of Hospitalizations
Total number of hospitalizations during the 24-month study period, including the reason for hospitalization (HIV-related or non-HIV-related) and the cumulative duration of hospitalization. Hospitalizations will be identified from medical records and study documentation.
Time frame: From enrollment through 24 months
Number of Emergency Department Visits
Total number of emergency department visits during the 24-month study period, including the primary reason for each visit. Emergency department visits will be identified from medical records and study documentation.
Time frame: From enrollment through 24 months
Health-Related Quality of Life (EQ-5D-3L Index Score)
Health-related quality of life assessed using the EuroQol Five-Dimension Three-Level (EQ-5D-3L) descriptive system. Responses across the five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on three levels, are converted to a single health utility index score using the \[specify value set, used., UK\] validated value set. Index scores range from -0.594 to 1.0 (using the UK value set; the exact minimum varies by value set), where 1.0 represents full health, 0 represents a health state equivalent to death, and negative values represent health states considered worse than death. Higher scores indicate better health-related quality of life." Note : why choosing (e.g. UK, Arab-region proxy) since Sudan does not yet have a locally derived value set. The minimum value will depend on that choice and should be explicitly stated.
Time frame: Baseline, 6 months, 12 months, 18 months, and 24 months
Health-Related Quality of Life - EQ-VAS Score
Health-related quality of life assessed using the EuroQol Visual Analogue Scale (EQ-VAS). Participants rate their overall health on a visual analogue scale from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better perceived health.
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Patient Satisfaction with Pharmaceutical Care
Patient satisfaction with pharmacist-provided pharmaceutical care assessed using a modified version of the Pharmaceutical Care Satisfaction Questionnaire (PCSQ). The modified instrument comprises \[X\] items, each rated on a \[Y\]-point Likert scale (e.g., 1 = strongly disagree to \[Y\] = strongly agree). Total scores range from \[minimum\] to \[maximum\], with higher scores indicating greater satisfaction with the pharmaceutical care services received."
Time frame: 6 months, 12 months, 18 months, and 24 months (MTM arms only)
Direct Medical Costs
Total direct medical costs from the healthcare system perspective, including costs associated with hospitalizations, emergency department visits, outpatient visits, laboratory tests, medications, and delivery of Medication Therapy Management (MTM) services. Costs will be reported in Sudanese Pounds (SDG) and converted to US Dollars (USD) using the prespecified exchange rate.
Time frame: From enrollment through 24 months
Serious Adverse Events (SAEs)
Number of serious adverse events (SAEs) occurring during the study period. An SAE is defined as any adverse event resulting in death, a life-threatening condition, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or another medically important event.
Time frame: From enrollment through 24 months
Medication Knowledge Score
Medication knowledge assessed using a validated 15-item medication knowledge questionnaire. Each correct response is assigned one point, with total scores ranging from 0 to 15. Higher scores indicate better medication knowledge. Medication knowledge assessed using the Note : This is a study-specific instrument developed for this trial, state: "a validated 15-item Medication Knowledge Questionnaire (MKQ) developed and validated for the purposes of this study."
Time frame: Baseline, 6 months, 12 months, 18 months, and 24 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Based on standard ethical and regulatory considerations for this study context, IPD will not be shared for the following reasons: Confidentiality of HIV status Participants are living with HIV in Sudan, where stigma and discrimination remain significant concerns. Sharing IPD could increase risk of unintended disclosure. Ethics committee restrictions The Sudanese Federal Ministry of Health Research Ethics Committee and USM JEPEM approvals likely restrict data sharing to protect vulnerable populations. No participant consent for data sharing The informed consent form (Appendices C and D) does not explicitly include permission for public data repository sharing. Local regulatory requirements Sudanese data protection and research regulations may prohibit transfer of HIVHIV-related data outside approved research teams.
Ran from Jan 2021 to primary completion in Jan 2023, 24 months.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 24 months is below that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.